Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How to deal with the hyperimmunized potential recipients.

B M Charpentier1, C Hiesse, F Kriaa

  • 1Nephrology Unit, Centre Hospitalo-Universitaire de Bicêtre, Kremlin Bicêtre, France.

Kidney International. Supplement
|October 1, 1992
PubMed
Summary

Managing highly sensitized end-stage renal disease patients awaiting kidney transplants is challenging. Immunoadsorption (IA) showed variable success in reducing panel reactive antibodies (PRA) and was hampered by antibody resynthesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incorporating the concept of overtransfusion into hemovigilance monitoring: An expert-based definition and criteria from the International HIT-OVER Forum.

Transfusion·2024
Same author

Circulating microaggregates as biomarkers for the Post-COVID syndrome.

IDCases·2024
Same author

A comparison of the new ROTEM<sup>®</sup> sigma with its predecessor, the ROTEMdelta.

Anaesthesia·2018
Same author

Fibrinogen supplementation ex vivo increasesclot firmness comparable to platelet transfusion in thrombocytopenia.

British journal of anaesthesia·2016
Same author

Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.

British journal of anaesthesia·2016
Same author

Fibrinogen concentrate improves clot strength in patients with haematological malignancies requiring platelet transfusion.

Transfusion medicine (Oxford, England)·2016

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • End-stage renal disease (ESRD) patients with high panel reactive antibodies (PRA) face significant delays in receiving kidney transplants due to sensitization from pregnancies, prior transplants, or transfusions.
  • A substantial proportion of patients awaiting transplantation, particularly in France, are sensitized (over 50%), with a significant subset being hyperimmunized (PRA >= 80%).
  • The limited availability of well-matched organs and challenges in cross-matching necessitate active strategies for managing highly sensitized recipients.

Purpose of the Study:

  • To evaluate the efficacy and safety of immunoadsorption (IA) as a strategy for managing highly sensitized ESRD patients awaiting kidney transplantation.
  • To assess the impact of IA, combined with immunosuppressive therapy, on reducing PRA levels and preventing antibody resynthesis.

Related Experiment Videos

Main Methods:

  • Fifteen ESRD patients with high PRA levels were treated with immunoadsorption (IA) using sepharose-bound protein-A columns.
  • Patients received adjunctive immunosuppressive treatment including cyclophosphamide and prednisolone.
  • The study monitored for infectious complications and assessed the tolerability of the IA procedure.

Main Results:

  • The IA procedure was well-tolerated, and no infectious complications were observed post-treatment or post-transplantation.
  • IA demonstrated variable effects in lowering PRA levels, even with adjunctive immunosuppressive therapy.
  • A significant challenge was the high rate of de novo anti-HLA antibody resynthesis following IA treatment.

Conclusions:

  • Immunoadsorption is a safe and well-tolerated procedure for highly sensitized ESRD patients.
  • IA alone or with current adjunctive therapies provides variable efficacy in reducing PRA and is significantly hampered by antibody resynthesis.
  • Further strategies are needed to overcome antibody resynthesis and improve outcomes for highly sensitized patients awaiting kidney transplantation.